ACOR Annual EBIT
-$264.49 M
-$259.44 M-5140.50%
31 December 2023
Summary:
As of January 30, 2025, ACOR annual earnings before interest & taxes is -$264.49 million, with the most recent change of -$259.44 million (-5140.50%) on December 31, 2023. During the last 3 years, it has fallen by -$187.40 million (-243.08%).ACOR EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACOR Quarterly EBIT
-$19.22 M
+$227.45 M+92.21%
31 March 2024
Summary:
As of January 30, 2025, ACOR quarterly earnings before interest & taxes is -$19.22 million, with the most recent change of +$227.45 million (+92.21%) on March 31, 2024. Over the past year, it has dropped by -$7.93 million (-70.26%).ACOR Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACOR TTM EBIT
-$271.77 M
-$7.93 M-3.01%
31 March 2024
Summary:
As of January 30, 2025, ACOR TTM earnings before interest & taxes is -$271.77 million, with the most recent change of -$7.93 million (-3.01%) on March 31, 2024. Over the past year, it has dropped by -$272.68 million (-30063.95%).ACOR TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACOR EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5140.5% | -70.3% | -10000.0% |
| 3 y3 years | -243.1% | +33.2% | -171.9% |
| 5 y5 years | -729.4% | +54.1% | -7.7% |
ACOR EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -594.4% | -127.3% | -478.9% |
Acorda Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | -$19.22 M(-92.2%) | -$271.77 M(+3.0%) |
| Dec 2023 | -$264.49 M(+5140.5%) | -$246.67 M(>+9900.0%) | -$263.84 M(-2139.4%) |
| Sept 2023 | - | -$2.31 M(-35.5%) | $12.94 M(+29.6%) |
| June 2023 | - | -$3.57 M(-68.4%) | $9.98 M(+1000.2%) |
| Mar 2023 | - | -$11.29 M(-137.5%) | $907.00 K(-120.1%) |
| Dec 2022 | -$5.05 M(-93.6%) | $30.11 M(-671.9%) | -$4.50 M(-90.2%) |
| Sept 2022 | - | -$5.26 M(-58.4%) | -$46.17 M(-27.8%) |
| June 2022 | - | -$12.64 M(-24.3%) | -$63.92 M(-4.5%) |
| Mar 2022 | - | -$16.70 M(+44.5%) | -$66.96 M(-15.3%) |
| Dec 2021 | -$79.04 M(+2.5%) | -$11.56 M(-49.8%) | -$79.04 M(-45.8%) |
| Sept 2021 | - | -$23.01 M(+46.6%) | -$145.87 M(+37.2%) |
| June 2021 | - | -$15.69 M(-45.5%) | -$106.29 M(+6.3%) |
| Mar 2021 | - | -$28.78 M(-63.3%) | -$99.97 M(+29.7%) |
| Dec 2020 | -$77.09 M(-69.5%) | -$78.39 M(-573.1%) | -$77.09 M(-207.5%) |
| Sept 2020 | - | $16.57 M(-276.9%) | $71.73 M(-135.2%) |
| June 2020 | - | -$9.37 M(+58.6%) | -$203.86 M(-5.8%) |
| Mar 2020 | - | -$5.90 M(-108.4%) | -$216.38 M(-14.3%) |
| Dec 2019 | -$252.38 M(-700.6%) | $70.43 M(-127.2%) | -$252.38 M(-32.0%) |
| Sept 2019 | - | -$259.02 M(+1083.1%) | -$371.00 M(+349.6%) |
| June 2019 | - | -$21.89 M(-47.7%) | -$82.51 M(>+9900.0%) |
| Mar 2019 | - | -$41.90 M(-13.1%) | -$652.00 K(-101.6%) |
| Dec 2018 | $42.02 M(-118.0%) | -$48.20 M(-263.5%) | $42.02 M(-132.8%) |
| Sept 2018 | - | $29.47 M(-50.9%) | -$127.92 M(-19.8%) |
| June 2018 | - | $59.97 M(+7637.7%) | -$159.53 M(-26.4%) |
| Mar 2018 | - | $775.00 K(-100.4%) | -$216.77 M(-7.1%) |
| Dec 2017 | -$233.22 M(+806.0%) | -$218.13 M(>+9900.0%) | -$233.22 M(+1722.3%) |
| Sept 2017 | - | -$2.15 M(-178.5%) | -$12.80 M(-21.3%) |
| June 2017 | - | $2.73 M(-117.4%) | -$16.26 M(-53.4%) |
| Mar 2017 | - | -$15.68 M(-783.8%) | -$34.89 M(+35.5%) |
| Dec 2016 | -$25.74 M(-173.9%) | $2.29 M(-140.9%) | -$25.74 M(+7.2%) |
| Sept 2016 | - | -$5.61 M(-64.7%) | -$24.01 M(-426.7%) |
| June 2016 | - | -$15.90 M(+143.3%) | $7.35 M(-75.0%) |
| Mar 2016 | - | -$6.53 M(-262.2%) | $29.38 M(-15.7%) |
| Dec 2015 | $34.84 M(-6.6%) | $4.03 M(-84.4%) | $34.84 M(+7.9%) |
| Sept 2015 | - | $25.75 M(+319.6%) | $32.29 M(+16.9%) |
| June 2015 | - | $6.14 M(-672.5%) | $27.63 M(-15.3%) |
| Mar 2015 | - | -$1.07 M(-172.5%) | $32.64 M(-12.5%) |
| Dec 2014 | $37.30 M | $1.48 M(-93.0%) | $37.30 M(-23.5%) |
| Sept 2014 | - | $21.09 M(+89.2%) | $48.73 M(+24.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | $11.14 M(+210.6%) | $39.18 M(+6.1%) |
| Mar 2014 | - | $3.59 M(-72.2%) | $36.94 M(+19.0%) |
| Dec 2013 | $31.03 M(+18.7%) | $12.91 M(+12.0%) | $31.03 M(+58.4%) |
| Sept 2013 | - | $11.53 M(+29.5%) | $19.59 M(+5.6%) |
| June 2013 | - | $8.91 M(-483.4%) | $18.56 M(+25.1%) |
| Mar 2013 | - | -$2.32 M(-257.3%) | $14.84 M(-43.3%) |
| Dec 2012 | $26.15 M(-26.5%) | $1.48 M(-85.9%) | $26.14 M(-30.9%) |
| Sept 2012 | - | $10.50 M(+102.7%) | $37.82 M(-21.4%) |
| June 2012 | - | $5.18 M(-42.3%) | $48.12 M(+9.4%) |
| Mar 2012 | - | $8.98 M(-31.7%) | $43.99 M(+23.6%) |
| Dec 2011 | $35.59 M(-553.5%) | $13.15 M(-36.8%) | $35.59 M(+33.4%) |
| Sept 2011 | - | $20.80 M(+1875.3%) | $26.68 M(+38.5%) |
| June 2011 | - | $1.05 M(+81.2%) | $19.26 M(+52.4%) |
| Mar 2011 | - | $581.00 K(-86.3%) | $12.63 M(-261.0%) |
| Dec 2010 | -$7.85 M(-90.3%) | $4.24 M(-68.3%) | -$7.85 M(-77.0%) |
| Sept 2010 | - | $13.38 M(-340.3%) | -$34.12 M(-48.7%) |
| June 2010 | - | -$5.57 M(-72.0%) | -$66.50 M(-20.0%) |
| Mar 2010 | - | -$19.90 M(-9.7%) | -$83.13 M(+2.3%) |
| Dec 2009 | -$81.26 M(+10.6%) | -$22.03 M(+16.0%) | -$81.26 M(+1.6%) |
| Sept 2009 | - | -$19.00 M(-14.4%) | -$80.01 M(-0.3%) |
| June 2009 | - | -$22.20 M(+23.1%) | -$80.27 M(+6.8%) |
| Mar 2009 | - | -$18.03 M(-13.3%) | -$75.14 M(+2.3%) |
| Dec 2008 | -$73.44 M(+86.2%) | -$20.79 M(+8.0%) | -$73.44 M(+9.3%) |
| Sept 2008 | - | -$19.25 M(+12.8%) | -$67.21 M(+18.1%) |
| June 2008 | - | -$17.07 M(+4.6%) | -$56.92 M(+18.7%) |
| Mar 2008 | - | -$16.32 M(+12.1%) | -$47.97 M(+21.6%) |
| Dec 2007 | -$39.45 M(+68.1%) | -$14.56 M(+62.5%) | -$39.45 M(+24.7%) |
| Sept 2007 | - | -$8.96 M(+10.4%) | -$31.64 M(+7.5%) |
| June 2007 | - | -$8.12 M(+4.0%) | -$29.43 M(+23.1%) |
| Mar 2007 | - | -$7.80 M(+15.6%) | -$23.91 M(+1.9%) |
| Dec 2006 | -$23.47 M(-31.8%) | -$6.75 M(+0.0%) | -$23.47 M(-8.5%) |
| Sept 2006 | - | -$6.75 M(+159.3%) | -$25.63 M(-2.0%) |
| June 2006 | - | -$2.60 M(-64.6%) | -$26.15 M(+11.1%) |
| Mar 2006 | - | -$7.36 M(-17.5%) | -$23.54 M(+45.5%) |
| Dec 2005 | -$34.41 M(-23.1%) | -$8.92 M(+22.7%) | -$16.19 M(+122.7%) |
| Sept 2005 | - | -$7.27 M(-69.1%) | -$7.27 M(-69.1%) |
| Dec 2004 | -$44.77 M(-28.3%) | - | - |
| Dec 2003 | -$62.48 M(+134.3%) | - | - |
| Sept 2003 | - | -$23.51 M | -$23.51 M |
| June 2003 | -$26.67 M | - | - |
FAQ
- What is Acorda Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Acorda Therapeutics?
- What is Acorda Therapeutics annual EBIT year-on-year change?
- What is Acorda Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Acorda Therapeutics?
- What is Acorda Therapeutics quarterly EBIT year-on-year change?
- What is Acorda Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Acorda Therapeutics?
- What is Acorda Therapeutics TTM EBIT year-on-year change?
What is Acorda Therapeutics annual earnings before interest & taxes?
The current annual EBIT of ACOR is -$264.49 M
What is the all time high annual EBIT for Acorda Therapeutics?
Acorda Therapeutics all-time high annual earnings before interest & taxes is $53.50 M
What is Acorda Therapeutics annual EBIT year-on-year change?
Over the past year, ACOR annual earnings before interest & taxes has changed by -$259.44 M (-5140.50%)
What is Acorda Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of ACOR is -$19.22 M
What is the all time high quarterly EBIT for Acorda Therapeutics?
Acorda Therapeutics all-time high quarterly earnings before interest & taxes is $70.43 M
What is Acorda Therapeutics quarterly EBIT year-on-year change?
Over the past year, ACOR quarterly earnings before interest & taxes has changed by -$7.93 M (-70.26%)
What is Acorda Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of ACOR is -$271.77 M
What is the all time high TTM EBIT for Acorda Therapeutics?
Acorda Therapeutics all-time high TTM earnings before interest & taxes is $71.73 M
What is Acorda Therapeutics TTM EBIT year-on-year change?
Over the past year, ACOR TTM earnings before interest & taxes has changed by -$272.68 M (-30063.95%)